Here are all the articles I could find quickly on Genzyme and Sanofi's latest machinations. Bottom line. They are still dickering on price and are trying to use CVRs to resolve differences in valuation. The valuation gap is largely caused by differing opinions on how long it will take Genzyme to correct its manufacturing deficiencies covered in the FDA decree and in th evalue that should be assigned to Genzyme's new MS drug should it gain approval.
In other words, same old, same old. Here are the list of articles and links:
Fierce Biotech coverage of CVRs in Sanofi-Genzyme and CVRs generally as biotech industry tool
Reuters report on deal and Sanofi drop in share price on latest news of talks
WSJ Health Blog is $80 per share the "magic number"
More from the In the Pipeline blog and Derek Lowe.
Posted by Bruce Lehr Jan 12th 2011.